Organization · Venture Capital
BroadOak Capital Partners
BroadOak Capital Partners is a boutique financial institution specializing in growth capital and advisory services for life sciences companies. With offices in Raleigh, Washington DC, and San Francisco, they focus on sectors such as diagnostics and biopharma services.
Overview
What BroadOak Capital Partners does
What BroadOak Capital Partners is
BroadOak Capital Partners is a boutique financial institution specializing in growth capital and advisory services for life sciences companies. With offices in Raleigh, Washington DC, and San Francisco, they focus on sectors such as diagnostics and biopharma services.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2006
- Approximate age
- About 20 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find BroadOak Capital Partners elsewhere
Open the official website or a supported primary organization account.
Capability profile
BroadOak Capital Partners as a funder
Investment thesis
BroadOak backs commercial-stage life sciences infrastructure businesses that are often misunderstood or overlooked by broader capital markets, focusing on companies with proven market need from initial revenue through profitability.
Focus narrative
BroadOak Capital Partners specializes in providing growth capital and advisory services to life sciences companies that are often underserved by traditional financial services. The firm focuses on commercial-stage companies with proven market needs for their products or services, allowing for various deal structures and investment sizes.
Value beyond capital
BroadOak Capital Partners adds value to its portfolio companies through deep sector expertise, operational experience, and a merchant-banking model that combines capital, M&A advice, and strategic support. Their flexible investment mandate allows them to tailor solutions to meet the unique needs of each company.
Focus and fit
- Stages
- Growth Equity
- Sectors
- Biotech · Healthcare · Diagnostics
- Regions
- Global · North America · Europe
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 120
Portfolio context
BroadOak has partnered with over 120 life sciences companies, including notable portfolio companies such as: Axol - specializing in life sciences tools; EpiCypher - focused on innovative solutions in the life sciences sector; Harvard Bioscience - engaged in the development of scientific instruments; IC Biomedical - providing specialized biomedical products; Azure Biosystems - offering advanced imaging and analysis solutions; Horizon Infusions - focusing on infusion therapy solutions; Microsize - specializing in microfluidics and related technologies.
Common questions
What to know about BroadOak Capital Partners
Upseed classifies BroadOak Capital Partners under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.